Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.65 |
| ▸ | HTR6 | P50406 | 2/20 | 0.65 |
| ▸ | HTR2A | P28223 | 4/20 | 0.60 |
| ▸ | HTR2C | P28335 | 2/20 | 0.60 |
| ▸ | HTR2B | P41595 | 2/20 | 0.60 |
| ▸ | BCHE | P06276 | 6/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24243750 | 0.90 | HTR2A (0.63) | HTR1AHTR6HTR2AHTR2CHTR2B | |
| SCHEMBL1969237 | 0.83 | HTR2A (0.68) | HTR1AHTR6HTR2AHTR2CHTR2B | |
| SCHEMBL24243697 | 0.82 | HTR2A (0.62) | HTR1AHTR6HTR2AHTR2CHTR2B | |
| SCHEMBL24692767 | 0.82 | MPO (0.68) | HTR1AHTR6HTR2AHTR2CHTR2B | |
| SCHEMBL24243773 | 0.80 | HTR1A (0.58) | HTR1AHTR6HTR2AHTR2CHTR2B | |
| SCHEMBL7336174 | 0.79 | HTR1A (0.47) | HTR1AHTR6HTR2AHTR2CHTR2B | |
| Diethyltryptamine SCHEMBL517713 | 0.79 | HTR1A (1.00) | HTR1AHTR6HTR2AHTR2CHTR2B | |
| SCHEMBL24243746 | 0.78 | HTR1A (0.74) | HTR1AHTR6HTR2AHTR2CHTR2B | |
| SCHEMBL29206484 | 0.78 | MPO (0.67) | HTR1AHTR6HTR2AHTR2CHTR2B | |
| SCHEMBL20970920 | 0.78 | HTR1A (0.74) | HTR1AHTR6HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220241243-A1 | METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. | 2022-08-04 | — | — | US | disclosed |
| US-20220041551-A1 | METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041551-A1 | METHODS OF TREATING MOOD DISORDERS | GRIN2C, GRIN2A, TPH2 | HTR1A 23/4885HTR6 13/4885HTR2A 5/4885 |
| US-20220241243-A1 | METHODS OF TREATING MOOD DISORDERS | GRIN2C, GRIN2A, TPH2 | HTR1A 23/4885HTR6 13/4885HTR2A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.